Therapeutic focus

  • 2 nd most common

    Cancer is the 2nd most common cause of death1

  • 19 million people

    19 million people were diagnosed with cancer in 20201

  • 30 million people

    30 million people are estimated to be diagnosed with cancer in 20402

1 World Cancer Research Fund
2 Global Oncology Trends 2019 – Therapeutics, Clinical Development and Health System Implications. IQVIA Institute for Human Data Science.

Vivesto’s technology and expertise can be applied in many different therapeutic areas, including oncology.

Techniques to improve drug solubility, such as the use of carriers in the form of polymers or oil derivatives may give rise to adverse effects that can be severe. This is a significant risk in patients who are seriously ill. Even so adverse effects caused by carriers has been accepted in cancer treatments due to the seriousness of the underlying disease.
Vivesto is active in the development of cancer therapies, with Apealea approved for use in advanced ovarian cancer in certain countries and in development to treat a variety of other common cancers.

Other cancers where Vivesto believes XR technology platform have potential to improve API solubility include prostate, lung, breast, ovarian, cervical and bladder.
Alongside the development of immuno-oncology drugs, small molecules are still the backbone of cancer treatment worldwide.1

1 1 Global oncology/cancer drugs market (2019), Allied Market Research